Impact of COVID-19 on Business Activities and Performance
First written in FY2020. 3 of 8 entries say "Materialised", first in FY2021-Q1. Latest entry: FY2022-Q3.
The whole theme swung hardest in 2024: 3 of 11 companies on the "Worse" side.
3 other companies' latest entry also says "Restated".
- FY2022-Q3RestatedAnnual report
「Although there are uncertain factors concerning the impact of COVID-19, the Group assumes that its impact on business performance is limited and that it will not have a significant impact on accounting estimates.」
The company has reiterated its view that, although there is uncertainty over the impact of COVID-19, its impact on business performance and accounting estimates is limited. - FY2022-Q2RestatedAnnual report
「Although there are uncertain factors concerning the impact of COVID-19, the Group assumes that its impact on business performance is limited and that it will not have a significant impact on accounting estimates.」
The company has reiterated its view that, although there is uncertainty over the impact of COVID-19, its impact on business performance and accounting estimates is limited. - FY2022-Q1RestatedAnnual report
「Although there are uncertain factors concerning the impact of COVID-19, the Group assumes that its impact on business performance is limited and that it will not have a significant impact on accounting estimates.」
The company has reiterated its view that, although there is uncertainty over the impact of COVID-19, its impact on business performance and accounting estimates is limited. - FY2021MitigatedAnnual report
「The impact of the spread of COVID-19 on the Group's performance has been limited, although there has been some impact from measures to prevent infection. The Group has advanced new business activities, including web-based meetings.」
While the impact of COVID-19 has continued, the company described the impact as limited due to new business activities such as web-based meetings. - FY2021-Q3MaterialisedAnnual report
「Performance for the nine months ended the third quarter continued to be affected by COVID-19 in the domestic pharmaceuticals and functional foods businesses, but」
The company reported that COVID-19 continued to affect the domestic pharmaceuticals and functional foods businesses. - FY2021-Q2MaterialisedAnnual report
「Performance for the six months ended the second quarter was affected by COVID-19 in the domestic pharmaceuticals and functional foods businesses. However, driven by growth in royalty income associated with overseas sales of Uptravi, the company's internally discovered treatment for pulmonary arterial hypertension, revenue increased 0.8% year on year to ¥57.817 billion.」
The company reported that COVID-19 continued to affect the domestic pharmaceuticals and functional foods businesses. - FY2021-Q1MaterialisedAnnual report
「Performance for the first quarter was affected by COVID-19 in the domestic pharmaceuticals and functional foods businesses, but」
COVID-19, which had been described as a future risk in the previous fiscal year, was reported to have actually affected the domestic pharmaceuticals and functional foods businesses. - FY2020First statedAnnual report
「The impact of the spread of COVID-19 on the Group's performance has been limited, although some patients have refrained from seeking medical care to prevent infection. The majority of sales consists of treatments for highly medically necessary areas, such as hematologic cancers and PAH. However, if COVID-19 were to spread further and economic activity in Japan and overseas were to stagnate, the Group's business performance could be affected.」
For COVID-19, the company had already recognized some impact from patients refraining from seeking medical care, but described the impact on current performance as limited and, for the first time, separately identified the potential future impact of the spread of infection and stagnation in economic activity as a risk.